Somatostatin receptors in GH-secreting pituitary adenomas - Their relationship to the response to octreotide

Endokrynologia Polska

Volumn 59, Issue 3, 2008, Pages 196-199

  Pawlikowski, Marek ^a   Pisarek, Hanna ^a   Kunert Radek, Jolanta ^a   Radek, Maciej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Acromegaly; Octreotide; Somatostain receptors

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE ANTIBODY; HORMONE ANTIBODY; HORMONE RECEPTOR; OCTREOTIDE; PROLACTIN ANTIBODY; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2A; SOMATOSTATIN RECEPTOR 2B; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ACROMEGALY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; ENDOCRINE SURGERY; GROWTH HORMONE SECRETING ADENOMA; HORMONE INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PROLACTINOMA; PROTEIN EXPRESSION;

ACROMEGALY; ADENOMA; ANTINEOPLASTIC AGENTS; GROWTH HORMONE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; IMMUNOHISTOCHEMISTRY; OCTREOTIDE; RECEPTORS, SOMATOSTATIN;

EID: 52249095742     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Mełeń-Mucha G, Mucha S. Somatostatin receptors: distribution in normal tissues and transduction mechanisms. In: Pawlikowski M (ed.). Somatostatin analogs in diagnosis and therapy. Landes Bioscience, Austin 2007: 7-20.
2. Alderton F, Fan TP, Schindler M. Rat somatostatin sst2(a) and sst2(b) receptor isoforms mediate opposite effects on cell proliferation. Br J Pharmacol 1998; 125: 1630-1633.
3. Pawlikowski M, Ławnicka H, Pisarek H et al. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro. J Physiol Pharmacol 2007; 58: 179-188.
4. Shimon I, Yan X, Taylor JE et al. Somatostatin receptor (SSTR) subtype - selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997; 100: 2386-2392.
5. Matrone C, Pivonello R, Colao A et al. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology 2004; 79: 142-148.
6. Panetta R, Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 1995; 56: 333-342.
7. Greenman Y, Melmed S. Expression of three somatostatin subtypes in pituitary adenomas: evidence of preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 1994; 79: 724-729.
8. Miller GM, Alexander JM, Bikkal HA et al. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 1995; 80: 1386-1392.
9. Nielsen S, Mellemkjaer S, Rasmussen LM. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo. J Endocrinol Invest 2001; 24: 430-437.
10. Makowska AM, Matyja E, Dudziak M et al. Expression of three somatostatin receptor subtypes (SSTR2A, SSTR3 and SSTR5) in secreting (HGH, PRL, ACTH) and non-functioning pituitary adenomas. In: Program & Abstracts, Endo2003, Philadelphia, June 19-22, 2003; P1-637 (abstract).
11. Scheithauer BW, Kovacs K, Horvath E. The Adenohypophysis. In: Bloodworth Endocrine Pathology, Lechago J, Gould VE (ed.). Williams and Wilkins, Baltimore 1997: 85-152.
12. Salehi F, Cohen S, Syro LV et al. Plurihormonality in pituitary adenomas associated with acromegaly. Endocr Pathol 2006; 17: 291-296.
13. Coculescu M, Badiu C, Galoiu S et al. Evolution under complex therapy of acromegaly due to a pituitary plurihormonal adenoma with colocalisation of GH and FSH. Acta Endocrinol 2006; 2: 337-348.
14. Ferone D, de Herder WW, Pivonello R et al. Correlation of in vitro and in vivo somatotrophic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrin Metab 2008 (in press).
15. Gruszka A, Kunert-Radek J, Radek A et al. The effect of seelective sst1, sst2, sst5 somatostatin receptor agonists, a somatostatin/dopamine (SST/ DA) chimera and bromocriptine on "clinically non-functioning" pituitary adenomas in vitro. Life Sci 2006, 78: 689-693.